EMEA-001830-PIP01-15-M02 - paediatric investigation plan
Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
PIPHuman
Seqirus S.r.l.
Tel. +39 0577096405; +39 0577096401
E-mail: pip.seq@seqirus.com
P/0188/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) (Foclivia and associated names), (EMEA- 001830-PIP01-1